GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs GM 6 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms GAP-PD
- 18 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 May 2013 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 16 May 2013 New source identified and integrated: ClinicalTrials.gov record.